For research and educational purposes only. Not medical advice.
GW-501516 Reference
Educational, not medical advice reference for GW-501516: SARM, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also known a…
Reference summary
Published work is preclinical, focused on PPARδ agonism, fatty-acid oxidation, and endurance phenotypes in rodents. No human clinical program; GSK halted development for rodent carcinogenicity.
- Categories
- SARM, Fat Loss
- Aliases
- Cardarine, Endurobol, PPARδ agonist, Non-SARM
- Evidence posture
- preclinical — Not a SARM — PPARδ agonist. GSK halted development after rodent studies showed multi-tissue carcinogenicity at active doses. WADA-prohibited under category S4.5 hormone and metabolic modulators at all times. FDA enforcement attention. No human clinical program for body-composition use.
- Regulatory status
- No FDA-approved GW-501516 drug label. WADA prohibits GW-501516 under category S4.5 hormone and metabolic modulators at all times. GSK halted development after rodent carcinogenicity studies showed multi-tissue tumors at active doses. FDA enforcement against SARMs sellers applies even though GW-501516 is technically a PPARδ agonist, not a SARM.
- Content review status
- research reference